Search for a trial

A Multicenter, Open-Label Study to Evaluate Fatigue in Subjects With Relapsing-Remitting Multiple Sclerosis During Treatment With Tecfidera® (Dimethyl Fumarate) Gastro-Resistant Hard Capsules (TECNERGY)

Primary:The primary objective of this study is to determine whether DMF taken over 12 months is effective in reducing MS-related fatigue, as measured by mean changes in the Fatigue Scale for Motor and Cognitive Functions (FSMC), in subjects with…

Towards personalized dosing of natalizumab in multiple sclerosis

Our main objective is to prove that extending dose intervals guided by serum concentrations of natalizumab, will not result in radiological or clinical disease activity.

Single arm study to assess comprehensive infusion guidance for the management of the infusion associated reaction (IARs) in Relapsing-Remitting Multiple Sclerosis (RRMS) patients treated with Lemtrada.

The objective of this study is to assess the distribution of infusion associated reactions (IARs) by severity grade when Lemtrada is administered to RRMS patients who will be medicated according to specified algorithm designed to manage infusion…

Immune regulation by dimethylfumarate (DMF) in patients with relapsing Remitting Multiple Sclerosis.

Primary objective: * Increases treatment with DMF the ability of Tregs to inhibit in relapsing-remitting MS patients? Proliferation of conventional T cells * Provides treatment with DMF to an increase in the number of nTreg (Foxp3 expression) or…

BENEFIT 11 a long-term, follow-up study (16401) of the BENEFIT (304747),
BENEFIT Follow-up (305207) Studies and BENEFIT Extension (311129) Study to
further evaluate the progress of patients with first demyelinating event suggestive of
multiple sclerosis

The primary objectives are to describe the disease course (conversion to clinically-definite multiple sclerosis [CDMS]), change in disability, cognitive function, resource use, and employment status, in relation to treatment with Interferon beta-1b…

An observational study on the effect of acupuncture with electric stimulation in multiple sclerosis patients with bladder dysfunction.

The research question which needs to be answered is: Is it feasible to recruit in 6 months a minimal of 20 patients with MS and bladder dysfunction to participate in an acupuncture study and are these patients compliant with the treatment and the…

BETAEVAL GLOBAL- The new BETACONNECT auto-injector: Adherence and EVALuation of MS patients treated with Betaferon®

To better understand the utilities of the new BETACONNECT device and characterize its contribution to adherence, we plan to prospectively follow-up MS patients using the device for 24 weeks.

A long-term follow-up study for Multiple Sclerosis patients who have completed the alemtuzumab Extension Study (CAMMS03409)

To evaluate the long-term safety and efficacy of alemtuzumab, for patients already treated with this medicine in preceding clinical trials (CARE-MS I, CARE-MS II and CAMMS03409).

A SINGLE ARM, OPEN LABEL MULTICENTRE EXTENSION STUDY TO EVALUATE THE EFFECTIVENESS AND SAFETY OF OCRELIZUMAB IN PATIENTS WITH MULTIPLE SCLEROSIS PREVIOUSLY ENROLLED IN A F. HOFFMANN-LA ROCHE SPONSORED OCRELIZUMAB PHASE IIIb/IV CLINICAL TRIAL

This study has been transitioned to CTIS with ID 2023-506543-41-00 check the CTIS register for the current data. This Extension study will evaluate the effectiveness and safety of ocrelizumab in MS patients who were previously enrolled in a Roche…

Multiple Sclerosis treatment with Autologous Hematopoietic Stem Cell Transplantation (MS-ACT): A long-term prospective observational study in the Netherlands

To perform long-term pre-specified follow-up of patients undergoing aHSCT for refractory RRMS.

A 2-year Prospective Study to Assess Health-related Quality of Life in Subjects with Highly-Active Relapsing Multiple Sclerosis Treated with Mavenclad®

synopsis:Primary:• To assess the health related quality of life (HRQoL) through the MSQoL-54 scale in highly-active relapsing multiple sclerosis (RMS) subjects treated with Mavenclad® for 2 years (24 months)Secondary:• To assess treatment…